Last reviewed · How we verify
Visken (PINDOLOL)
At a glance
| Generic name | PINDOLOL |
|---|---|
| Sponsor | Novartis |
| Drug class | beta-Adrenergic Blocker [EPC] |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Hypertensive disorder
Common side effects
- Edema
- Dizziness
- Fatigue
- Insomnia
- Nervousness
- Abdominal Discomfort
- Nausea
- Pruritus
- Rash
- Dyspnea
- Joint Pain
- Muscle Cramps
Drug interactions
- piroxicam
- sulindac
- tolazamide
- tolbutamide
- verapamil
Key clinical trials
- A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) (PHASE2)
- N-of-1 for Beta-Blockers in Cardiac Amyloidosis (PHASE4)
- A Preliminary Study for INFORMED (PHASE4)
- Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors (NA)
- Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (PHASE2)
- Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF (PHASE4)
- Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV) (PHASE1)
- Impact of Beta-blockers on Physical Function in HFpEF (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Visken CI brief — competitive landscape report
- Visken updates RSS · CI watch RSS